A key proposed change is the expansion of IBC oversight beyond recombinant and synthetic nucleic acid research to include a wider range of biohazardous research activities, including certain wild-type biological agents requiring BSL-2 containment or higher. If adopted as written, many research activities currently taking place across campus without IBC registration or review would become subject to IBC oversight. This includes research involving wild-type BSL-2 agents and activities that are currently exempt from IBC review, such as work with many E. coli K-12 strains and derivatives and the purchase or transfer of transgenic rodents. Investigators who have not historically needed IBC approval may be required to submit protocols for review and approval before conducting these activities. 

The draft policy also includes substantially enhanced transparency requirements. IBC meeting minutes and certain incident reports would be publicly posted using new NIH-standardized templates. The proposed minutes and incident reporting templates require disclosure of more information than is currently shared publicly.

EHS is evaluating the potential impact of these changes on university review processes, submission requirements, and approval timelines. Additional information about the draft policy and associated resources can be found using the links below:

EHS will continue to provide updates as implementation details become available.